Prof Matti Aapro speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about some of the issues surrounding breast cancer treatment.

He begins by discussing whether CDK4/6 inhibitors should be combined with endocrine therapy as a first-line treatment in patients who present with metastatic disease.

Prof Aapro also explores the use of trastuzumab in the adjuvant setting and questions whether it should be used for 12 months versus 6 months.